• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
LVTX

LVTX

LAVA Therapeutics N.V.

NASDAQHealthcareBiotechnologyNL

USD1.74

-0.07 (-3.87%)

Company Profile

CEO

Stephen Allen Hurly

IPO Date

2021-03-26

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

NL

Market Metrics

Open

$1.74

Prev. Close

$1.74

Day Low

$1.74

Day High

$1.74

52W Low

$0.85

52W High

$2.00

Market Cap

$0.05B

Volume

0.29M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

6

Avg Positive

23.3%

Avg Negative

1.3%

Avg Neutral

75.0%

News Feed

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies

GlobeNewsWire·7/13/2021·↑ positive

LAVA Therapeutics to Present at 2021 Jefferies Virtual Healthcare Conference

GlobeNewsWire·5/25/2021·↑ positive

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

GlobeNewsWire·5/20/2021·↑ positive

LAVA Therapeutics to Present at 2021 UBS Global Healthcare Virtual Conference

GlobeNewsWire·5/18/2021·↑ positive

LAVA Therapeutics Appoints Karen J. Wilson to its Board of Directors

GlobeNewsWire·4/1/2021·↑ positive

LAVA Therapeutics Announces Pricing of Initial Public Offering

GlobeNewsWire·3/24/2021·↑ positive